See more : TV18 Broadcast Limited (TV18BRDCST.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Mural Oncology plc (MURA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mural Oncology plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Money Forward, Inc. (3994.T) Income Statement Analysis – Financial Results
- Seagate Technology Holdings plc (0Y2A.L) Income Statement Analysis – Financial Results
- ShoulderUp Technology Acquisition Corp. (SUAC-UN) Income Statement Analysis – Financial Results
- Signaux Girod S.A. (ALGIR.PA) Income Statement Analysis – Financial Results
- Plantronics, Inc. (POLY) Income Statement Analysis – Financial Results
Mural Oncology plc (MURA)
About Mural Oncology plc
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.57M | 1.54M | 1.47M |
| Gross Profit | -2.57M | -1.54M | -1.47M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 162.03M | 170.07M | 159.82M |
| General & Administrative | 30.71M | 25.08M | 15.55M |
| Selling & Marketing | -667.00K | 0.00 | 0.00 |
| SG&A | 30.04M | 25.08M | 15.55M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 192.07M | 195.15M | 175.37M |
| Cost & Expenses | 194.64M | 195.15M | 175.37M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.57M | 1.54M | 1.47M |
| EBITDA | -192.72M | -183.38M | -173.89M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -194.64M | -195.15M | -175.37M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -649.00K | 10.22M | 0.00 |
| Income Before Tax | -195.29M | -195.15M | -175.37M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 12.16M | 4.88M | 68.00K |
| Net Income | -207.45M | -200.03M | -175.43M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -12.43 | -11.99 | -10.51 |
| EPS Diluted | -12.43 | -11.99 | -10.51 |
| Weighted Avg Shares Out | 16.69M | 16.69M | 16.69M |
| Weighted Avg Shares Out (Dil) | 16.69M | 16.69M | 16.69M |
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
For the first time, the company shares data for its preclinical IL-18 and IL-12 programs—candidate nominations for each are expected later this year Combination of IL-18 binding protein resistance with additional half-life enhancement to IL-18 variant demonstrated durable immunological effects...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. and DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to...
Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H 2025 Newly recommended phase 2 dose of nemvaleukin with...
Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced two...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of...
Recent Spin Mural Oncology At An Attractive Discount To Cash And Portfolio Value
Mural Oncology trades at approximately $5, a material discount to cash holdings of over $16/share, as reported in November 2023. The pipeline of 3 major candidates of cytokine cancer therapies at different stages in clinical trials may offer material value...
Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference
DUBLIN, Ireland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of...
Why Is Mural Oncology (MURA) Stock Up 59% Today?
Mural Oncology (NASDAQ:MURA) stock is rising higher on Friday after the company was separated from Alkermes (NASDAQ: ALKS ). This separation went into effect on Nov. 15 and sees Mural Oncology now acting as its own independent company listed separately from...
Source: https://incomestatements.info
Category: Stock Reports